Navigation Links
Analysis of drug-eluting stents data demonstrates safety, efficacy in on-and-off-label use
Date:6/16/2009

NEW YORK, NY JUNE 16, 2009 The Cardiovascular Research Foundation (CRF) announced that results of the largest meta-analysis to date comparing mortality rates for drug-eluting stents (DES) versus bare metal stents (BMS) were published online June 15 in the journal Circulation. The study also compared the rates of myocardial infarction (MI) and target vessel revascularization (TVR).

The analysiswhich includes approximately 190,000 patients from 56 studieswas performed by a team of researchers led by Ajay J. Kirtane, MD, Assistant Professor of Clinical Medicine at Columbia University College of Physicians and Surgeons; and an interventional cardiologist at NewYork-Presbyterian Hospital/Columbia University Medical Center; and Gregg W. Stone, MD, Immediate Past Chairman of the Cardiovascular Research Foundation; Professor of Medicine at Columbia University College of Physicians and Surgeons; and Director of Cardiovascular Research and Education in the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center.

Drs. Kirtane and Stone conducted two parallel meta-analyses examining DES vs. BMS use in both randomized, controlled trials and in observational registry analyses. The overall analysis represents the largest systematic overview of "real-world" (comprising both on-label and off-label) DES use to date and incorporates an overview of both the published literature as well as several unpublished studies presented at major cardiovascular meetings.

"The findings from these parallel studies are striking," said Dr. Stone.

The meta-analysis of 22 randomized trials included more than 9,000 patients with recent follow-up from previously published trials. According to the results, "DES resulted in no overall differences in death and MI, with a greater than 50% decrease in subsequent target vessel revascularization procedures," said Dr. Stone, adding that these findings are consistent with both on-label and off-label use of DES.

And in the 34-study observational meta-analysis (involving more than 180,000 "real-world" patients), "DES resulted in significant 22% and 13% reductions in death and MI, respectively, with a similar reduction in TVR (46%) as in the randomized trials, even after adjustment for confounding variables," said Dr. Stone. "These data are reassuring that DES are safe and effective for a wide-range of patients that are able to take dual antiplatelet therapy for at least one year."

The findings were consistent and robust across a variety of study designs; trials that were included were required to follow patients for at least one year.

Dr. Kirtane remarked that these findings should help to reassure patients and physicians about the safety of DES in off-label use.

"One of the interesting aspects of this analysis is that it points to significant differences between results obtained from randomized trials and observational analyses. Nonetheless, even with the stated limitations of observational data, the bottom line from both randomized trials and observational analyses is consistent: we can reduce the need for repeat procedures and we do not appear to be harming patients with DES," he added.


'/>"/>

Contact: Judy Romero
jromero@crf.org
212-851-9311
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Broadlane Selects Silver Creek Systems To Accelerate Core Business Analysis And New Client Services
2. Lethality of H1N1 Influenza Virus Increasing According to Latest Replikin Analysis of Virus Peptide Genomic Data
3. Analysis Sheds Light on Proteins Role in Cancer
4. Ambry Genetics Announces Launch of Chromosomal Microarray to Offer Whole Genome Analysis
5. Evidence-Based Analysis of Aspartame Research
6. Ingenuity and Integromics Offer Integration for Comprehensive Genomics Analysis
7. Milliman Analysis: Preparing for Mental Health Parity
8. NSD Bio Group, LLC Selected By U.S. - China Economic & Security Review Commission for Analysis of Chinas Pharma Supply Chain on U.S. Pharmaceuticals
9. Medicaid Health Plans Provide Cost Savings to States and High Quality and Value to Beneficiaries, New Analysis Shows
10. Transplant patients have worse cancer outcomes, analysis shows
11. Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... ... February 21, 2017 , ... Each February the nation ... (officially African American History Month ). This month-long celebration encourages ... diverse race of people, but also the opportunity to examine the trends of ...
(Date:2/21/2017)... ... 2017 , ... One of the most prevalent health conditions ... and financial consequences of inaction. On March 3, World Hearing Day, the American ... about their hearing. , Effective treatment in the form of hearing aids and ...
(Date:2/21/2017)... (PRWEB) , ... February 21, 2017 , ... Along with ... healthy lifestyle and make small changes that can lead to a lifetime of heart ... possibility of a cardiac emergency. , The Athletic Trainers’ Society of New ...
(Date:2/20/2017)... ... 2017 , ... Nancy Johnston Toll marks her debut in the ... the Bump in the Road ” (published by Xlibris). Inspired from her personal experiences, ... the ups and downs experienced by anyone going through cancer treatment and how one ...
(Date:2/20/2017)... ... 2017 , ... Scrubbing in for his first esophageal cancer case in the ... excitement of the surgeon training him. , “He was giddy and almost couldn’t contain ... anyone, but I would do it for free,’” Dr. Pezzi recalled. “He genuinely was ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... and Markets has announced the addition of the "Liver Cirrhosis Drugs ... ... Drugs Price Analysis and Strategies - 2016, provides drug pricing data and ... the following questions: What are the key drugs ... in the Global Liver Cirrhosis market? What are the ...
(Date:2/21/2017)... 21, 2017 Research and Markets has announced the ... report to their offering. ... The latest research Anthrax Drugs Price Analysis and Strategies - 2016, ... The research answers the following questions: What ... are they positioned in the Global Anthrax market? What ...
(Date:2/20/2017)... 20, 2017 Provides understanding and access ... into by the worlds leading healthcare companies. ... Description The Global Anemia Partnering Terms and Agreements ... partnering deals and agreements entered into by the ... in partnering deals - Top deals by ...
Breaking Medicine Technology: